Insight Molecular Diagnostics (IMDX) Other Accumulated Expenses (2016 - 2026)

Insight Molecular Diagnostics (IMDX) has 7 years of Other Accumulated Expenses data on file, last reported at $2.7 million in Q1 2026.

• Quarterly Other Accumulated Expenses changed N/A year-over-year to $2.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (changed N/A YoY) and the FY2025 annual result came in at $2.8 million, up 335.74% from the prior year.
• Other Accumulated Expenses declined to $2.7 million in Q1 2026 per IMDX's latest filing, from $2.8 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $2.8 million in Q4 2025, with the low at $638000.0 in Q4 2024.
• Average Other Accumulated Expenses over 3 years is $2.1 million, with a median of $2.7 million recorded in 2026.
• The widest YoY moves for Other Accumulated Expenses: up 335.74% in 2025, down 335.74% in 2025.
• Insight Molecular Diagnostics' Other Accumulated Expenses stood at $638000.0 in 2024, then surged by 335.74% to $2.8 million in 2025, then retreated by 1.58% to $2.7 million in 2026.
• Business Quant data shows IMDX's Other Accumulated Expenses at $2.7 million in Q1 2026, $2.8 million in Q4 2025, and $638000.0 in Q4 2024.